Platform will simplify workflows and expand use of TaqMan® assays for a wide range of genotyping applications
SOURCE: Applied Biosystems and BioTrove, Inc.
FOSTER CITY, Calif. and WOBURN, Mass. – November 12, 2007 – Applied Biosystems (NYSE: ABI), an Applera Corporation business, today announced that it has signed a licensing and collaboration agreement with BioTrove, Inc. to commercialize an analysis platform for high-throughput genotyping applications. Applied Biosystems will develop and market custom-built arrays of TaqMan® SNP Genotyping Assays pre-loaded on BioTrove’s OpenArray™ platform. This platform will integrate the ease-of-use, accuracy, and reproducibility of Applied Biosystems’ TaqMan SNP Genotyping Assays with BioTrove’s flexible high-density assay format, enabling researchers to rapidly perform high-throughput genotyping studies at a lower total cost compared to alternative commercially available methods.
Under terms of the agreement, Applied Biosystems retains the rights to commercialize all genotyping applications, including assays other than ones based on TaqMan technology, for BioTrove’s platform. Applied Biosystems plans to commercialize and service all components of this analysis platform during the second half of 2008. Applied Biosystems is also retaining an option to collaborate with BioTrove, Inc. for developing and commercializing the OpenArray platform for high-throughput gene expression applications.
In a separate agreement, Applied Biosystems has granted a worldwide license under patent rights related to
real-time thermal cyclers, microfluidics, and data analysis to BioTrove, Inc. Under the agreement, BioTrove will have the right to manufacture and sell real-time thermal cyclers and array sample loaders in the life-sciences research field, as well as to develop further real-time PCR applications for its OpenArray platform. Financial terms of the agreements were not disclosed.
Overall, this collaboration is expected to expand the potential uses of TaqMan technology across a wide range of genomic applications. The genotyping platform provides an extremely fast, high-throughput screening and validation tool for researchers in agricultural, pharmaceutical, and other commercial industries, as well as academic institutions. Examples of studies that should benefit from the use of this platform include those that associate genotypes with: complex diseases, varied responses of individuals to different treatments for disease, measurable traits for quality control in agricultural studies, and the identity of different pathogens in biosecurity applications.
When pre-loaded with TaqMan SNP Genotyping Assays, BioTrove’s OpenArray platform enables researchers to perform genotyping studies that investigate tens to hundreds of single base changes, or SNPs (single nucleotide polymorphisms) across hundreds to thousands of samples. This scale of genotyping study is often performed as part of breeding and quality control processes in the agricultural industry. In these applications, researchers investigate how SNPs from multiple genes contribute to measurable traits. These SNPs are then used as genetic markers for quality control testing, tracking, or selective breeding of crops and livestock. Alternatively, large-scale disease association studies can involve over 10,000 to 20,000 samples and also require high sample throughput technology to ensure efficient genotyping across candidate SNPs.
Researchers using this integrated platform can experience an end-to-end genotyping workflow of less than four hours, enabling them to analyze thousands of samples in days in contrast to weeks on alternative genotyping platforms. As the OpenArray platform consumes less reagent per assay (33 nl per reaction) than current alternative commercially available offerings, applications can be performed in a more cost-effective manner.
“We believe that customers in industries such as health care, food, and agriculture will benefit from a cost-effective, flexible genotyping solution that combines Applied Biosystems’ gold-standard TaqMan assay products with BioTrove’s flexible high-throughput OpenArray platform,” said Peter Dansky, president for Applied Biosystems’ molecular and cell biology consumables business. “This collaboration will provide researchers and commercial organizations with a validation and screening tool that has the potential to dramatically improve genotyping workflows critical to the success of their enterprise.”
The razor-thin BioTrove OpenArray consumable device has a flexible array format that enables researchers to perform more than 3,000 different high-throughput genotyping assays in a variety of different configurations. For example, using one OpenArray slide, researchers can genotype as many as 144 samples, and interrogate 16 SNPs per sample, or, in a single sample, interrogate as many as 3,072 SNPs.
The OpenArray platform will provide researchers with customized arrays of TaqMan SNP Genotyping Assays from a single source, simplifying their workflow for performing a variety of high-throughput genotyping applications. Researchers will be able to select assays from Applied Biosystems’ comprehensive line of more than 4.5 million individual pre-designed TaqMan® SNP Genotyping Assays, Custom TaqMan® SNP Genotyping Assays, or TaqMan® DME Genotyping Assays for detecting polymorphisms in the drug metabolism enzyme genes. Once customers receive their assays pre-loaded on BioTrove’s OpenArray™ consumable devices, they will then use an automated sample loader to introduce their DNA samples into the arrays. After a short processing time, the OpenArray slides are read by the accompanying software to determine sample genotype.
“The strength of the product design resulting from this collaboration provides researchers in public and private industries with the speed, flexibility, and cost-effectiveness of the BioTrove OpenArray platform and the specificity and reproducibility of Applied Biosystems’ comprehensive line of TaqMan assay products – all in a single solution,” said Al Luderer, Ph.D., president and CEO of BioTrove, Inc. “By streamlining researchers’ genotyping workflows, we are accelerating the discovery and utilization of science impacting public health—from healthier foods to better health care.”
Applied Biosystems is a global leader in the development and commercialization of instrument-based systems, consumables, software, and services for the life-science market. Applied Biosystems has pre-designed more than 700,000 TaqMan® Gene Expression Assays and more than 4.5 million TaqMan® SNP Genotyping Assays. Complementing these off-the-shelf products are custom TaqMan® assays, which are available for customer-specific gene expression or genotyping targets, and TaqMan DME Genotyping Assays. More information about Applied Biosystems’ complete line of gene expression and genotyping solutions is available at: http://info.appliedbiosystems.com.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. Applied Biosystems serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, such as testing required for food and pharmaceutical manufacturing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. Celera is a diagnostics business delivering personalized disease management solutions through a combination of tests and services based on proprietary genetics discovery platforms. The business is developing diagnostic products that predict disease risk and optimize therapy selection and patient outcomes, based on the discovery and validation of novel markers in complex diseases such as cardiovascular disease, breast cancer, and liver and autoimmune diseases. Celera also maintains a strategic alliance with Abbott for the development and commercialization of some of its molecular diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.
About BioTrove, Inc.
BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world’s ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.
The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.
For more information, please visit www.biotrove.com.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “should, “planned,” and “expect,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers’ capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
For Research Use Only. Not for use in diagnostic procedures. Practice of the patented 5’ Nuclease Process requires a license from Applied Biosystems.
Applera, Applied Biosystems, and AB (Design) are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc.
Copyright © 2007. Applera Corporation. All rights reserved.
BioTrove, OpenArray, RapidFire, and the BioTrove logo are trademarks of BioTrove, Inc.
Copyright © 2007. BioTrove, Inc. All rights reserved.